Share Price and Basic Stock Data
Last Updated: February 3, 2026, 1:51 am
| PEG Ratio | 6.02 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alembic Pharmaceuticals Ltd, a prominent player in the Indian pharmaceuticals industry, reported a market capitalization of ₹15,385 Cr and a current share price of ₹782. The company’s sales figures have shown a consistent upward trend, with reported sales of ₹5,653 Cr for the financial year ending March 2023, increasing to ₹6,229 Cr for FY 2024, and further rising to ₹6,672 Cr projected for FY 2025. This growth trajectory is indicative of robust demand for its pharmaceutical products, which is crucial for sustaining its competitive position in a dynamic market. Notably, sales for the quarter ended September 2023 stood at ₹1,595 Cr, reflecting a year-on-year increase, while the trailing twelve months (TTM) revenue reached ₹7,083 Cr. The company’s operational performance, characterized by a steady increase in revenue, positions Alembic well against industry benchmarks, highlighting its ability to capitalize on market opportunities.
Profitability and Efficiency Metrics
Alembic Pharmaceuticals has demonstrated commendable profitability metrics, with a net profit of ₹632 Cr reported for FY 2025, translating to a net profit margin of 8.71%. The operating profit margin (OPM) stood at 15.74% for the same fiscal year, indicating efficient cost management and operational effectiveness. The return on equity (ROE) was recorded at 11.4%, while the return on capital employed (ROCE) was 13%, both figures reflecting the company’s effective utilization of shareholder equity and capital. The interest coverage ratio (ICR) of 13.34x showcases a strong ability to meet interest obligations, enhancing financial stability. However, the company’s cash conversion cycle (CCC) has lengthened to 363 days, suggesting potential challenges in managing working capital efficiently. This metric, combined with a decrease in the inventory turnover ratio to 3.39x, warrants attention as it may impact liquidity in the short term.
Balance Sheet Strength and Financial Ratios
Alembic Pharmaceuticals reported total assets of ₹7,773 Cr for FY 2025, with total liabilities at ₹7,773 Cr, indicating a balanced financial structure. The company maintained a conservative debt profile, with total borrowings of ₹1,489 Cr, resulting in a low total debt-to-equity ratio of 0.23x, which is significantly lower than industry averages. The reserves stood at ₹5,280 Cr, reflecting a solid buffer for future investments and operational stability. The book value per share increased to ₹264.10 in FY 2025, signifying an increase in intrinsic value for shareholders. Furthermore, the current ratio of 1.69x indicates adequate liquidity to meet short-term obligations. These financial ratios demonstrate a strong balance sheet that supports Alembic’s growth initiatives while mitigating financial risks.
Shareholding Pattern and Investor Confidence
The shareholding structure of Alembic Pharmaceuticals reveals a significant level of promoter confidence, with promoters holding 69.74% of the equity as of September 2025. This stable ownership by the founding family suggests strong alignment with long-term business goals. Institutional investors, including foreign institutional investors (FIIs) at 4.04% and domestic institutional investors (DIIs) at 16.30%, contribute to the company’s credibility and governance standards. However, the public shareholding has declined to 9.92%, which could indicate a lack of retail investor interest in recent periods. The number of shareholders stood at 89,969, reflecting a decrease from previous quarters. This decline, coupled with the high promoter shareholding, could raise concerns about liquidity and market participation among retail investors, impacting overall market perception.
Outlook, Risks, and Final Insight
The outlook for Alembic Pharmaceuticals appears promising, driven by consistent revenue growth and strong profitability metrics. However, the company faces risks related to its elongated cash conversion cycle and declining inventory turnover, which may affect liquidity in the short term. Additionally, the pharmaceutical sector is subject to regulatory challenges and pricing pressures that could impact future profitability. The company’s capacity to innovate and expand its product portfolio will be crucial for maintaining competitive advantage. A focused strategy on operational efficiency and working capital management will be essential in mitigating these risks. Should Alembic successfully address these challenges, it may enhance its market position, driving further growth and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,475 | 1,509 | 1,406 | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 |
| Expenses | 1,244 | 1,274 | 1,203 | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 |
| Operating Profit | 231 | 235 | 204 | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 |
| OPM % | 16% | 16% | 14% | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% |
| Other Income | 0 | 0 | 1 | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 |
| Interest | 12 | 15 | 14 | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 |
| Depreciation | 68 | 67 | 74 | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 |
| Profit before tax | 151 | 154 | 116 | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 |
| Tax % | 12% | 21% | -31% | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% |
| Net Profit | 133 | 122 | 153 | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 |
| EPS in Rs | 6.78 | 6.20 | 7.76 | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 |
Last Updated: January 2, 2026, 1:34 pm
Below is a detailed analysis of the quarterly data for Alembic Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,910.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,711.00 Cr. (Jun 2025) to 1,910.00 Cr., marking an increase of 199.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,594.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,430.00 Cr. (Jun 2025) to 1,594.00 Cr., marking an increase of 164.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 316.00 Cr.. The value appears strong and on an upward trend. It has increased from 281.00 Cr. (Jun 2025) to 316.00 Cr., marking an increase of 35.00 Cr..
- For OPM %, as of Sep 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Jun 2025) to 17.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 24.00 Cr..
- For Depreciation, as of Sep 2025, the value is 76.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 74.00 Cr. (Jun 2025) to 76.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 190.00 Cr. (Jun 2025) to 224.00 Cr., marking an increase of 34.00 Cr..
- For Tax %, as of Sep 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 19.00% (Jun 2025) to 18.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Jun 2025) to 184.00 Cr., marking an increase of 30.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 9.40. The value appears strong and on an upward trend. It has increased from 7.85 (Jun 2025) to 9.40, marking an increase of 1.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,863 | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,083 |
| Expenses | 1,506 | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 5,955 |
| Operating Profit | 358 | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,128 |
| OPM % | 19% | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 16% |
| Other Income | 4 | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | 39 |
| Interest | 10 | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 95 |
| Depreciation | 40 | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 289 |
| Profit before tax | 311 | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 784 |
| Tax % | 24% | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | 3% | 18% | |
| Net Profit | 236 | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 632 |
| EPS in Rs | 12.49 | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 32.27 |
| Dividend Payout % | 24% | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | 35% | 37% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 19.92% | 154.42% | -44.03% | 2.48% | 41.16% | 37.39% | 43.07% | -54.54% | -34.36% | 80.12% | -5.52% |
| Change in YoY Net Profit Growth (%) | 0.00% | 134.50% | -198.44% | 46.51% | 38.68% | -3.77% | 5.68% | -97.61% | 20.18% | 114.47% | -85.64% |
Alembic Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 8% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 14% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 10:45 pm
Balance Sheet
Last Updated: December 10, 2025, 2:20 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 638 | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,280 |
| Borrowings | 109 | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 | 1,489 |
| Other Liabilities | 432 | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,324 | 1,589 |
| Total Liabilities | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,397 |
| Fixed Assets | 397 | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 2,834 |
| CWIP | 21 | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 | 903 |
| Investments | 3 | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 129 |
| Other Assets | 796 | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 | 4,531 |
| Total Assets | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,397 |
Below is a detailed analysis of the balance sheet data for Alembic Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 39.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 39.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,152.00 Cr. (Mar 2025) to 5,280.00 Cr., marking an increase of 128.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,489.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,258.00 Cr. (Mar 2025) to 1,489.00 Cr., marking an increase of 231.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,589.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,324.00 Cr. (Mar 2025) to 1,589.00 Cr., marking an increase of 265.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,397.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,773.00 Cr. (Mar 2025) to 8,397.00 Cr., marking an increase of 624.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,834.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,524.00 Cr. (Mar 2025) to 2,834.00 Cr., marking an increase of 310.00 Cr..
- For CWIP, as of Sep 2025, the value is 903.00 Cr.. The value appears strong and on an upward trend. It has increased from 837.00 Cr. (Mar 2025) to 903.00 Cr., marking an increase of 66.00 Cr..
- For Investments, as of Sep 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2025) to 129.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4,531.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,285.00 Cr. (Mar 2025) to 4,531.00 Cr., marking an increase of 246.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,397.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,773.00 Cr. (Mar 2025) to 8,397.00 Cr., marking an increase of 624.00 Cr..
Notably, the Reserves (5,280.00 Cr.) exceed the Borrowings (1,489.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 249.00 | 139.00 | -113.00 | 526.00 | -65.00 | 873.00 | 0.00 | -583.00 | 157.00 | -40.00 | 419.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 |
| Inventory Days | 159 | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 |
| Days Payable | 148 | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 |
| Cash Conversion Cycle | 65 | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 |
| Working Capital Days | 45 | 32 | 36 | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 |
| ROCE % | 44% | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% | 13% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Small Cap Fund | 3,427,766 | 1.68 | 290.04 | N/A | N/A | N/A |
| DSP Mid Cap Fund | 2,122,883 | 0.92 | 179.63 | 2,129,889 | 2025-12-15 00:56:17 | -0.33% |
| DSP Small Cap Fund | 1,500,000 | 0.75 | 126.92 | 1,409,091 | 2025-12-08 05:15:13 | 6.45% |
| Axis Small Cap Fund | 1,455,416 | 0.46 | 123.15 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,443,386 | 1.89 | 122.13 | 1,316,201 | 2026-01-25 12:49:34 | 9.66% |
| DSP ELSS Tax Saver Fund | 1,434,898 | 0.69 | 121.41 | 1,252,667 | 2025-12-08 05:15:13 | 14.55% |
| DSP Healthcare Fund | 1,428,180 | 3.88 | 120.85 | 1,423,563 | 2025-12-08 05:15:13 | 0.32% |
| DSP Aggressive Hybrid Fund | 810,789 | 0.56 | 68.6 | N/A | N/A | N/A |
| DSP Large Cap Fund | 608,603 | 0.71 | 51.5 | N/A | N/A | N/A |
| ICICI Prudential Smallcap Fund | 477,105 | 0.48 | 40.37 | 470,000 | 2026-01-26 08:54:41 | 1.51% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 |
| Diluted EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 |
| Cash EPS (Rs.) | 43.74 | 45.25 | 32.99 | 40.83 | 66.05 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
| Revenue From Operations / Share (Rs.) | 339.46 | 316.90 | 287.59 | 269.95 | 274.39 |
| PBDIT / Share (Rs.) | 53.46 | 48.93 | 36.18 | 47.04 | 79.75 |
| PBIT / Share (Rs.) | 39.29 | 35.05 | 22.17 | 32.45 | 70.42 |
| PBT / Share (Rs.) | 35.94 | 32.20 | 19.61 | 31.55 | 69.60 |
| Net Profit / Share (Rs.) | 29.57 | 31.38 | 18.97 | 26.23 | 56.72 |
| NP After MI And SOA / Share (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 59.94 |
| PBDIT Margin (%) | 15.74 | 15.43 | 12.58 | 17.42 | 29.06 |
| PBIT Margin (%) | 11.57 | 11.06 | 7.70 | 12.02 | 25.66 |
| PBT Margin (%) | 10.58 | 10.15 | 6.82 | 11.68 | 25.36 |
| Net Profit Margin (%) | 8.71 | 9.90 | 6.59 | 9.71 | 20.67 |
| NP After MI And SOA Margin (%) | 8.74 | 9.88 | 6.05 | 9.81 | 21.84 |
| Return on Networth / Equity (%) | 11.23 | 12.78 | 7.82 | 9.94 | 22.97 |
| Return on Capital Employeed (%) | 14.40 | 13.80 | 9.58 | 11.79 | 25.49 |
| Return On Assets (%) | 7.50 | 9.55 | 5.53 | 7.31 | 17.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Total Debt / Equity (X) | 0.23 | 0.08 | 0.14 | 0.12 | 0.03 |
| Asset Turnover Ratio (%) | 0.93 | 0.98 | 0.77 | 0.73 | 0.79 |
| Current Ratio (X) | 1.69 | 2.12 | 1.78 | 1.67 | 2.01 |
| Quick Ratio (X) | 0.74 | 0.98 | 0.87 | 0.72 | 0.85 |
| Inventory Turnover Ratio (X) | 3.39 | 0.89 | 0.86 | 0.78 | 0.93 |
| Dividend Payout Ratio (NP) (%) | 37.06 | 25.53 | 57.47 | 52.82 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 25.08 | 17.69 | 31.83 | 34.06 | 0.00 |
| Earning Retention Ratio (%) | 62.94 | 74.47 | 42.53 | 47.18 | 0.00 |
| Cash Earning Retention Ratio (%) | 74.92 | 82.31 | 68.17 | 65.94 | 0.00 |
| Interest Coverage Ratio (X) | 13.34 | 17.11 | 14.17 | 52.15 | 97.85 |
| Interest Coverage Ratio (Post Tax) (X) | 8.21 | 11.98 | 8.43 | 30.08 | 70.59 |
| Enterprise Value (Cr.) | 19368.46 | 19611.97 | 10301.50 | 15131.79 | 19003.45 |
| EV / Net Operating Revenue (X) | 2.90 | 3.15 | 1.82 | 2.85 | 3.52 |
| EV / EBITDA (X) | 18.43 | 20.39 | 14.49 | 16.37 | 12.12 |
| MarketCap / Net Operating Revenue (X) | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 |
| Retention Ratios (%) | 62.93 | 74.46 | 42.52 | 47.17 | 0.00 |
| Price / BV (X) | 3.52 | 4.01 | 2.23 | 2.78 | 3.70 |
| Price / Net Operating Revenue (X) | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 |
After reviewing the key financial ratios for Alembic Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For Diluted EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For Cash EPS (Rs.), as of Mar 25, the value is 43.74. This value is within the healthy range. It has decreased from 45.25 (Mar 24) to 43.74, marking a decrease of 1.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 339.46. It has increased from 316.90 (Mar 24) to 339.46, marking an increase of 22.56.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.46. This value is within the healthy range. It has increased from 48.93 (Mar 24) to 53.46, marking an increase of 4.53.
- For PBIT / Share (Rs.), as of Mar 25, the value is 39.29. This value is within the healthy range. It has increased from 35.05 (Mar 24) to 39.29, marking an increase of 4.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 35.94. This value is within the healthy range. It has increased from 32.20 (Mar 24) to 35.94, marking an increase of 3.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 29.57. This value is within the healthy range. It has decreased from 31.38 (Mar 24) to 29.57, marking a decrease of 1.81.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For PBDIT Margin (%), as of Mar 25, the value is 15.74. This value is within the healthy range. It has increased from 15.43 (Mar 24) to 15.74, marking an increase of 0.31.
- For PBIT Margin (%), as of Mar 25, the value is 11.57. This value is within the healthy range. It has increased from 11.06 (Mar 24) to 11.57, marking an increase of 0.51.
- For PBT Margin (%), as of Mar 25, the value is 10.58. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 10.58, marking an increase of 0.43.
- For Net Profit Margin (%), as of Mar 25, the value is 8.71. This value is within the healthy range. It has decreased from 9.90 (Mar 24) to 8.71, marking a decrease of 1.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.74. This value is within the healthy range. It has decreased from 9.88 (Mar 24) to 8.74, marking a decrease of 1.14.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.23. This value is below the healthy minimum of 15. It has decreased from 12.78 (Mar 24) to 11.23, marking a decrease of 1.55.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.40. This value is within the healthy range. It has increased from 13.80 (Mar 24) to 14.40, marking an increase of 0.60.
- For Return On Assets (%), as of Mar 25, the value is 7.50. This value is within the healthy range. It has decreased from 9.55 (Mar 24) to 7.50, marking a decrease of 2.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.23, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.93. It has decreased from 0.98 (Mar 24) to 0.93, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.69, marking a decrease of 0.43.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.74, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.39. This value is below the healthy minimum of 4. It has increased from 0.89 (Mar 24) to 3.39, marking an increase of 2.50.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.06. This value is within the healthy range. It has increased from 25.53 (Mar 24) to 37.06, marking an increase of 11.53.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.08. This value is within the healthy range. It has increased from 17.69 (Mar 24) to 25.08, marking an increase of 7.39.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.94. This value is within the healthy range. It has decreased from 74.47 (Mar 24) to 62.94, marking a decrease of 11.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.92. This value exceeds the healthy maximum of 70. It has decreased from 82.31 (Mar 24) to 74.92, marking a decrease of 7.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.34. This value is within the healthy range. It has decreased from 17.11 (Mar 24) to 13.34, marking a decrease of 3.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.21. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 8.21, marking a decrease of 3.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 19,368.46. It has decreased from 19,611.97 (Mar 24) to 19,368.46, marking a decrease of 243.51.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.90. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.90, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 18.43. This value exceeds the healthy maximum of 15. It has decreased from 20.39 (Mar 24) to 18.43, marking a decrease of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
- For Retention Ratios (%), as of Mar 25, the value is 62.93. This value is within the healthy range. It has decreased from 74.46 (Mar 24) to 62.93, marking a decrease of 11.53.
- For Price / BV (X), as of Mar 25, the value is 3.52. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.52, marking a decrease of 0.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alembic Pharmaceuticals Ltd:
- Net Profit Margin: 8.71%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.4% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.23% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.2 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.23
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.71%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Alembic Road, Vadodra Gujarat 390003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chirayu Amin | Chairman & CEO |
| Mr. Pranav Amin | Managing Director |
| Mr. Shaunak Amin | Managing Director |
| Mr. R K Baheti | Director - Finance & CFO |
| Mr. Jai Diwanji | Independent Director |
| Mr. Ashok Barat | Independent Director |
| Ms. Geeta Goradia | Independent Director |
| Mr. Manish Kejriwal | Independent Director |
FAQ
What is the intrinsic value of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's intrinsic value (as of 05 February 2026) is ₹630.91 which is 19.32% lower the current market price of ₹782.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹15,385 Cr. market cap, FY2025-2026 high/low of ₹1,108/725, reserves of ₹5,280 Cr, and liabilities of ₹8,397 Cr.
What is the Market Cap of Alembic Pharmaceuticals Ltd?
The Market Cap of Alembic Pharmaceuticals Ltd is 15,385 Cr..
What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 05 February 2026?
The current stock price of Alembic Pharmaceuticals Ltd as on 05 February 2026 is ₹782.
What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alembic Pharmaceuticals Ltd stocks is ₹1,108/725.
What is the Stock P/E of Alembic Pharmaceuticals Ltd?
The Stock P/E of Alembic Pharmaceuticals Ltd is 24.2.
What is the Book Value of Alembic Pharmaceuticals Ltd?
The Book Value of Alembic Pharmaceuticals Ltd is 271.
What is the Dividend Yield of Alembic Pharmaceuticals Ltd?
The Dividend Yield of Alembic Pharmaceuticals Ltd is 1.41 %.
What is the ROCE of Alembic Pharmaceuticals Ltd?
The ROCE of Alembic Pharmaceuticals Ltd is 13.0 %.
What is the ROE of Alembic Pharmaceuticals Ltd?
The ROE of Alembic Pharmaceuticals Ltd is 11.4 %.
What is the Face Value of Alembic Pharmaceuticals Ltd?
The Face Value of Alembic Pharmaceuticals Ltd is 2.00.